Free Republic

The most common cancer in women — and one of the deadliest — may have finally met its match. Development of a breakthrough vaccine researchers say could eradicate breast cancer by 2030 wrapped up phase one of its clinical trial this week, with more than 75% of women showing a strong immune response, as measured by antibodies on their white blood cells. The vaccine is aimed at both preventing and treating breast cancer — which affects one in eight women. “It’s very exciting,” said Dr. Amit Kumar, CEO of Anixa Biosciences, which is designing the vaccine along with the Cleveland...

SUNDAY, April 13 (HealthDay News) — A breast cancer vaccine significantly reduced the risk of recurrence for patients who have a high expression of the protein HER2-neu. This type of breast cancer, representing about one-quarter of all cases, tends to be deadlier than other forms of the disease. In this group, the vaccine reduced mortality by 50 percent. Even better, however, the vaccine lowered mortality by 100 percent in women with breast cancer and low or intermediate expression of HER2/neu. Currently, these women have no therapies other than conventional cancer treatments such as surgery and chemo. "We now have something...